NovalGen Ltd., a biopharmaceutical company developing breakthrough cancer therapies and Halix B.V., a contract development and manufacturing organization, have entered a strategic partnership in which Halix will provide manufacturing of clinical supply of NovalGen’s therapies.   NovalGen’s platform technology has been successfully deployed at Halix to manufacture clinical trial material for NovalGen’s first clinical program. The program, NVG-111, is a Receptor Tyrosine Kinase Like Orphan Like Re...